(+)-JQ1

Name: (+)-JQ1
Brand: Selleck Chemicals
SKU: S7110
Rating: 5 (203 reviews)

For research use only. Not for use in humans.

Catalog No.S7110

203 publications

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Selleck's (+)-JQ1 has been cited by 203 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2018, 34(2):271-285.e7

PubMed: 30107177 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Nat Med, 2017, 23(4):493-500

PubMed: 28263307 ( click the link to review the publication )

Nat Med, 2017, 23(9):1046-1054

PubMed: 28805821 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Gastroenterology, 2014, 147(5):1119-33

PubMed: 25127677 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Sci Transl Med, 2019, 11(497)

PubMed: 31217338 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Commun, 2019, 10(1):335

PubMed: 30659195 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

Nucleic Acids Res, 2019, gkz1139

PubMed: 31822909 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0682-7

PubMed: 31862959 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(6):2220-2225

PubMed: 30659143 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2415-2425

PubMed: 30885979 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Theranostics, 2019, 9(13):3840-3852

PubMed: 31281517 ( click the link to review the publication )

Cancer Res, 2019, 79(19):4869-4881

PubMed: 31311807 ( click the link to review the publication )

Cancer Res, 2019, 79(18):4599-4611

PubMed: 31358529 ( click the link to review the publication )
Cell Rep, 2019, 28(13):3497-3509

PubMed: 31553917 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):73

PubMed: 31288832 ( click the link to review the publication )

Redox Biol, 2019, 24:101195

PubMed: 31004990 ( click the link to review the publication )

Oncogene, 2019, 38(47):7249-7265

PubMed: 31420604 ( click the link to review the publication )

Cancer Lett, 2019, 442:373-382

PubMed: 30419347 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):383

PubMed: 31470872 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):557

PubMed: 31324754 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):324

PubMed: 30975979 ( click the link to review the publication )

Cell Death Dis, 2019, 10(11):815

PubMed: 31653826 ( click the link to review the publication )

Addict Biol, 2019, 10.1111/adb.12808

PubMed: 31364211 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2111-2123

PubMed: 31467179 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2019, 10.1016/j.jtcvs.2019.06.115

PubMed: 31564537 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13305

PubMed: 31527644 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17369

PubMed: 31758083 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Biomed Pharmacother, 2019, 114:108793

PubMed: 30921702 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(3):481-488

PubMed: 31530390 ( click the link to review the publication )
J Oral Pathol Med, 2019, 10.1111/jop.12906

PubMed: 31177574 ( click the link to review the publication )

SLAS Discov, 2019, 24(2):142-157

PubMed: 30204533 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):499-507

PubMed: 30483785 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2340-2347

PubMed: 31452730 ( click the link to review the publication )

Journal of Oral Pathology & Medicine, 2019, 10.1111/jop.12906

PubMed: 无 ( click the link to review the publication )

Mol Cell, 2018, 72(2):341-354

PubMed: 30270106 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1532

PubMed: 29670088 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3815

PubMed: 30232459 ( click the link to review the publication )

EMBO J, 2018, 37(5)

PubMed: 29440228 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(40):E9317-E9324

PubMed: 30181285 ( click the link to review the publication )

J Am Soc Nephrol, 2018, 29(6):1690-1705

PubMed: 29739813 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

Cell Rep, 2018, 22(8):2016-2025

PubMed: 29466730 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )

Oncogene, 2018, 37(28):3763-3777

PubMed: 29636547 ( click the link to review the publication )

J Med Chem, 2018, 61(2):453-461

PubMed: 28378579 ( click the link to review the publication )

Cancers (Basel), 2018, 10(1)

PubMed: 29346274 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Cells, 2018, 7(10)

PubMed: 30304769 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e419

PubMed: 29303513 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 50(2):798-809

PubMed: 30308485 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2796-2810

PubMed: 30242092 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )
Gynecol Oncol, 2018, 149(3):575-584

PubMed: 29567272 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(2)

PubMed: 29118124 ( click the link to review the publication )

Epigenetics Chromatin, 2018, 11(1):30

PubMed: 29884215 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Sci Rep, 2018, 8(1):998

PubMed: 29343723 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

Int J Oncol, 2018, 53(6):2503-2517

PubMed: 30272279 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2018, 59(1):132-143

PubMed: 29332125 ( click the link to review the publication )

Bioorg Med Chem, 2018, 26(1):25-36

PubMed: 29170024 ( click the link to review the publication )

Int J Stem Cells, 2018, 11(1):131-140

PubMed: 29699387 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 499(3):531-537

PubMed: 29596834 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(4):931-940

PubMed: 28750570 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(5):1248-1251

PubMed: 28885069 ( click the link to review the publication )

Oncotarget, 2018, 9(71):33482-33499

PubMed: 30323893 ( click the link to review the publication )

Blood Adv, 2018, 2(23):3428-3442

PubMed: 30504235 ( click the link to review the publication )

Oncotarget, 2018, 9(11):9907-9924

PubMed: 29515779 ( click the link to review the publication )

Oncotarget, 2018, 9(41):26491-26506

PubMed: 29899872 ( click the link to review the publication )

Oncotarget, 2018, 9(83):35408-35421

PubMed: 30459933 ( click the link to review the publication )

JCI Insight, 2018, 3(19)

PubMed: 30282829 ( click the link to review the publication )
JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8:14802

PubMed: 28378740 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(14):8403-8410

PubMed: 28854735 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(15):4462-4472

PubMed: 28270499 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(36):E7554-E7563

PubMed: 28784769 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(27):E5352-E5361

PubMed: 28630312 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(43):E9135-E9144

PubMed: 29073110 ( click the link to review the publication )

Genes Dev, 2017, 31(12):1212-1227

PubMed: 28724615 ( click the link to review the publication )

Cancer Res, 2017, 77(20):5564-5575

PubMed: 28819026 ( click the link to review the publication )

J Am Soc Nephrol, 2017, 28(2):504-519

PubMed: 27436852 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cell Rep, 2017, 21(10):2796-2812

PubMed: 29212027 ( click the link to review the publication )

Haematologica, 2017, 102(10):1776-1784

PubMed: 28751557 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Sci Signal, 2017, 10(508)

PubMed: 29208683 ( click the link to review the publication )

J Med Chem, 2017, 60(24):9990-10012

PubMed: 29172540 ( click the link to review the publication )

J Med Chem, 2017, 60(14):6289-6304

PubMed: 28650658 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1436-1449

PubMed: 28923910 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1739-1750

PubMed: 28572168 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1155-1165

PubMed: 28246302 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2017, 1863(12):3001-3015

PubMed: 28844955 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):35-44

PubMed: 27707886 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8027

PubMed: 28808321 ( click the link to review the publication )

Skelet Muscle, 2017, 7(1):16

PubMed: 28870238 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Org Biomol Chem, 2017, 15(44):9352-9361

PubMed: 29087414 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(22):4384-4394

PubMed: 28471170 ( click the link to review the publication )

Cell Biosci, 2017, 7:56

PubMed: 29118968 ( click the link to review the publication )

Molecules, 2017, 23(1)

PubMed: 29295560 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2581-2593

PubMed: 28553123 ( click the link to review the publication )

J Gen Virol, 2017, 98(4):799-809

PubMed: 28113052 ( click the link to review the publication )

Biol Res, 2017, 50(1):19

PubMed: 28545522 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37140-37153

PubMed: 28415755 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8334-8349

PubMed: 29492199 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98068-98083

PubMed: 29228674 ( click the link to review the publication )
Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51402-51415

PubMed: 28881656 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98471-98481

PubMed: 29228703 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16646

PubMed: 29192216 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(7):504-10

PubMed: 27159579 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2448

PubMed: 27401245 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(42):11865-11870

PubMed: 27679845 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(31):E4558-66

PubMed: 27432991 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(17):4440-51

PubMed: 27103402 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1204-13

PubMed: 26837760 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )

Cell Rep, 2016, 16(5):1366-1378

PubMed: 27425608 ( click the link to review the publication )

Cell Rep, 2016, 15(2):310-22

PubMed: 27050521 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):134

PubMed: 27903272 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Cancer Discov, 2016, 6(6):612-29

PubMed: 27099234 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0750

PubMed: 26939702 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1217-26

PubMed: 26983878 ( click the link to review the publication )

J Virol, 2016, 90(18):8059-73

PubMed: 27356901 ( click the link to review the publication )
J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

Oncol Rep, 2016, 36(4):1989-96

PubMed: 27573714 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 469(3):679-85

PubMed: 26707881 ( click the link to review the publication )

Oncotarget, 2016, 6(7):5134-46

PubMed: 25762617 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6576-92

PubMed: 26536665 ( click the link to review the publication )

Sci Rep, 2016, 6:23770

PubMed: 27044328 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Blood, 2015, 126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:10091

PubMed: 26631872 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Cancer Res, 2015, 75(21):4548-59

PubMed: 26483207 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:121

PubMed: 26515759 ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Arch Toxicol, 2015, 89(2):179-91

PubMed: 25559776 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1034416

PubMed: 25941994 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Sci Rep, 2015, 5:10120

PubMed: 25944566 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Exp Ther Med, 2015, 10(6):2319-2324

PubMed: 26668635 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Nat Chem Biol, 2014, 10(4):305-12

PubMed: 24584101 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2014, 111(26):E2721-30

PubMed: 24979794 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):9503-8

PubMed: 24979803 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7090-102

PubMed: 25277525 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5999-6009

PubMed: 25164011 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(11):2896-910

PubMed: 25106422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Drug Metab Dispos, 2013, 41(10):1725-31

PubMed: 23918665 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63563

PubMed: 23704919 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Handb Exp Pharmacol, 2011, 206:1-12

PubMed: 21879443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description

Features

(+)-JQ1 is more effective than (-)-JQ1.

Targets

BRD4 (2) ^[1] (Cell-free assay)	BRD4 (1) ^[1] (Cell-free assay)
33 nM	77 nM

In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. ^[1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. ^[2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. ^[3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
K1	NVPLTm1pS2WubDDWbYFjcWyrdImgRZN{[Xl?	NGDadYozPTBxNUCwM\|ExODBibl2=	NUHFd4lkOjRxNEivO\|IhcA>?	MX\EUXNQ	M3\l[IlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	NFvqZ2MzPjdyN{i4NS=>
BCPAP	MoD5R4VtdCCYaXHibYxqfHliQYPzZZk>	NHrFcGgzPTBxNUCwM\|ExODBibl2=	Mm[2NlQwPDhxN{KgbC=>	M123fGROW09?	MWfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	Ml3uNlY4ODd6OEG=
K1	MWnD[YxtKEO7Y3zlJGF{e2G7	NXva[Y5pOjVyL{WwNE8yODByIH7N	MYi3NkBp	NH:3SGVFVVOR	NXXFellx[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl	Mo\nNlY4ODd6OEG=
BCPAP	NY[yR45RS2WubDDDfYNt\SCDc4PhfS=>	M4HqUFI2OC93MECvNVAxOCCwTR?=	NU\mWYFYPzJiaB?=	M3qwbmROW09?	NILmOHZienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS\|EheGijc3W=	Mo[yNlY4ODd6OEG=
Hep3B	NFrLdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;kS5MxNTFyIN88US=>	MVK1JIQ>	MWPEUXNQ	MXvJR\|UxRTBwMEig{txO	NH\KdJIzPjV5NUG2Oy=>
HCCLM3	Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXySXR1OC1zMDFOwG0>	MYW1JIQ>	NEfRTIZFVVOR	MYDJR\|UxRTBwMUSg{txO	NInaRoEzPjV5NUG2Oy=>
HuH7	NGPnZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfDNE0yOCEQvF2=	MnXJOUBl	NGDCWZBFVVOR	NGfRSVFKSzVyPUCuNlEh\|ryP	Mnj2NlY2PzVzNke=
HepG2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX:wMVExKM7:TR?=	M1TV[\|Uh\A>?	M2O1VWROW09?	MkfITWM2OD1yLkO0JO69VQ>?	NIfCemMzPjV5NUG2Oy=>
SMMC7721	MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnS3NE0yOCEQvF2=	MYm1JIQ>	MXnEUXNQ	NGHV[VRKSzVyPUCuOFEh\|ryP	MnvMNlY2PzVzNke=
BEL7402	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTLVVlsOC1zMDFOwG0>	NWL0eWdZPSCm	MnTtSG1UVw>?	MUDJR\|UxRTBwNEeg{txO	NGHlfHEzPjV5NUG2Oy=>
MHCC97H	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HrSlAuOTBizszN	NWnteVgzPSCm	MmfLSG1UVw>?	NV7ISpBEUUN3ME2wMlQyKM7:TR?=	NXX2N4Y3OjZ3N{WxOlc>
Hep3B	NVnub2x6S2WubDDDfYNt\SCDc4PhfS=>	MUiwMlEwOC53L{KuOUDPxE1?	NXj5VGpwPDhiaB?=	M3\VUmROW09?	MWHs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA>	M4L1T\|I3PTd3MU[3
HCCLM3	NFrxZ4tE\WyuIFP5Z4xmKEG\|c3H5	M4judlAvOS9yLkWvNk42KM7:TR?=	MVW0PEBp	M2X6SGROW09?	MlvrcIVi\HNidH:gZUB{fWK\|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh	MUmyOlU4PTF4Nx?=
Hep3B	MkTQRZBweHSxc3nzJGF{e2G7	M{fmbVAvOS9yLkWvNk42KM7:TR?=	MW[0PEBp	NGnPPXpFVVOR	MXPhZ5RqfmG2ZYOgZ4F{eGG\|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli	MWOyOlU4PTF4Nx?=
HCCLM3	MYTBdI9xfG:\|aYOgRZN{[Xl?	M2[0ZlAvOS9yLkWvNk42KM7:TR?=	M2e3d\|Q5KGh?	NWHyeYs{TE2VTx?=	MXPhZ5RqfmG2ZYOgZ4F{eGG\|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli	M3HhTlI3PTd3MU[3
A549	NX\5Tm41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjKSIMxNjFvMUCg{txO	NGfoSWU4OiCq		MojLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MWeyOlQyPTJ{NR?=
H157	NWH6XXlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37PWFAvOS1zMDFOwG0>	NYDCVVY6PzJiaB?=		MXvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MXWyOlQyPTJ{NR?=
H1299	Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYGwMlEuOTBizszN	NHTkOpo4OiCq		MXrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MUOyOlQyPTJ{NR?=
A549	NWTEUY9GTnWwY4Tpc44hSXO\|YYm=	NYHXbZJFOS9{LkWvOUDPxE1?	MVuxNkBp		MV9CpJdm[WuueTDk[YNz\WG\|ZXSgRoNtNTJibHX2[Yx{	M4HWclI3PDF3MkK1
H1299	NHzlN5dHfW6ldHnvckBCe3OjeR?=	MXWxM\|IvPS93IN88US=>	NXPnOYI3OTJiaB?=		MUpCpJdm[WuueTDk[YNz\WG\|ZXSgRoNtNTJibHX2[Yx{	MkLCNlY1OTV{MkW=
H157	NHrWVYxHfW6ldHnvckBCe3OjeR?=	MUexM\|IvPS93IN88US=>	MYqxNkBp		M{O4N4Rm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?=	MoHBNlY1OTV{MkW=
H1299	NHzSc3pHfW6ldHnvckBCe3OjeR?=	NE\2THQyNzJwNT:1JO69VQ>?	M3PZXVEzKGh?		M3vtOIRm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?=	NHHGcXIzPjRzNUKyOS=>
C8161	NIPENWdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NWO3e5YxOC1{IN88US=>	MV:0JIQ>	NFG5Tm1FVVOR	M4S2W4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFj1c4czPjN7N{KyNy=>
Mel285	MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MV[wMVIh\|ryP	M3PVclQh\A>?	M2[yUmROW09?	MmDz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MkT2NlY{QTd{MkO=
Mel290	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MVGwMVIh\|ryP	NFzPd4I1KGR?	MXHEUXNQ	Ml6y[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MmP0NlY{QTd{MkO=
92.1	M1jtVmNmdGxiVnnhZoltcXS7IFHzd4F6	NHvVZpQxNTJizszN	NGPjWnE1KGR?	MmnpSG1UVw>?	Ml3X[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NHWy[YUzPjN7N{KyNy=>
Omm1.3	Ml7PR4VtdCCYaXHibYxqfHliQYPzZZk>	M{PlZlAuOiEQvF2=	M4TwWlQh\A>?	MWfEUXNQ	Moe4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MWCyOlM6PzJ{Mx?=
Mel202	NIDnclNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXywMVIh\|ryP	NVzTXYplPCCm	MUHEUXNQ	NYT0Zot6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFrlZnIzPjN7N{KyNy=>
Mel270	M360b2NmdGxiVnnhZoltcXS7IFHzd4F6	NILQNJIxNTJizszN	NU\DfZZqPCCm	MmXCSG1UVw>?	MWTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M{HvUFI3Ozl5MkKz
Omm1	M1jON2NmdGxiVnnhZoltcXS7IFHzd4F6	NWjydoxZOC1{IN88US=>	NGHUbmY1KGR?	NWLs[JhWTE2VTx?=	MmCz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	Mn;VNlY{QTd{MkO=
92.1	M3W4[WFxd3C2b4Ppd{BCe3OjeR?=	NIC3bZg2ODBibl2=	MWC0PEBp	NFHHOWlFVVOR	MU\pcoR2[2W\|IHHwc5B1d3Orcx?=	M4f2blI3Ozl5MkKz
Omm1.3	MVPBdI9xfG:\|aYOgRZN{[Xl?	NXTqOnN3PTByIH7N	M4XpVlQ5KGh?	NU\s[Vd1TE2VTx?=	Mn3rbY5lfWOnczDhdI9xfG:\|aYO=	NYrPdGlqOjZ\|OUeyNlM>
92.1	NGDKOIxE\WyuIFP5Z4xmKEG\|c3H5	M4Cwd\|UxOCCwTR?=	M37DR\|I1NzR6L{eyJIg>	MULEUXNQ	MYjpcoR2[2W\|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC\|dXKtS\|HDqA>?	NULqSo1yOjZ\|OUeyNlM>
Omm1.3	MnXhR4VtdCCFeXPs[UBCe3OjeR?=	MojoOVAxKG6P	MnzKNlQwPDhxN{KgbC=>	MlywSG1UVw>?	NXfKVVVVcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC=	Mn\yNlY{QTd{MkO=
A549	NEHUc3hHfW6ldHnvckBCe3OjeR?=	NELnOJoyODBxNECwM\|ExODBibl2=	MlG1NlQhcA>?		MVz1dJJm\3WuYYTld{BidmRiYXP0bZZifGW\|IGPJVnQy	NFrN[XozPjJzMkG5PS=>
MCF-7	NXm3NYVxTnWwY4Tpc44hSXO\|YYm=	NYmyblQxOTByL{SwNE8yODByIH7N	NGXGNJIzPCCq		M2DHRpVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF?	MUmyOlIyOjF7OR?=
HEK293	M2[4OmZ2dmO2aX;uJGF{e2G7	NHz1RVgyODBxNECwM\|ExODBibl2=	NYGz[pZUOjRiaB?=		M2HOUJVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF?	MmjkNlYzOTJzOUm=
858	M{jDOWNmdGxiVnnhZoltcXS7IFHzd4F6	M2rpblAuOSEQvF2=	MYG1JIQ>	M1q0VmROW09?	Ml\4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MonZNlYzODZ\|M{O=
DDR2L63V	NWfxcY5GS2WubDDWbYFjcWyrdImgRZN{[Xl?	MmjRNE0yKM7:TR?=	M32zOVUh\A>?	MYHEUXNQ	NHO3WWll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MX[yOlIxPjN\|Mx?=
BE(2)-C	MoOxR4VtdCCYaXHibYxqfHliQYPzZZk>	MV:xJO69VQ>?	NGL2cJEyNTRiZB?=		MX\k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=>	NWLzT\|NHOjZyNke0OlQ>
IMR-32	MnnuR4VtdCCYaXHibYxqfHliQYPzZZk>	NW\2O4JxOSEQvF2=	M3jmWlEuPCCm		M2n5c4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	NWnJVJl6OjZyNke0OlQ>
JF	M4PscGNmdGxiVnnhZoltcXS7IFHzd4F6	M3PIOlEh\|ryP	NIDrN3cyNTRiZB?=		NYj6bHY2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	M3jPWFI3ODZ5NE[0
BE(2)-M17	MlrtR4VtdCCYaXHibYxqfHliQYPzZZk>	Ml72NUDPxE1?	MUexMVQh\A>?		NGiy[\|Vl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	MkKxNlYxPjd2NkS=
SK-N-SH	Mlr5R4VtdCCYaXHibYxqfHliQYPzZZk>	M{fQ[VEh\|ryP	MYCxMVQh\A>?		M3KxVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	MXyyOlA3PzR4NB?=
SK-N-DZ	NV;RNGh3S2WubDDWbYFjcWyrdImgRZN{[Xl?	MWCxJO69VQ>?	MnHJNU01KGR?		M{ixOoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	MnXwNlYxPjd2NkS=
HMC-1.1	NIfTd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nxNFUuPTByMDDuUS=>	MonBOFghcA>?	Moi1SG1UVw>?	NWHVdGhkcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M1n4fVI3ODV3M{Cz
HMC-1.2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPWOU02ODByIH7N	MYS0PEBp	MmjzSG1UVw>?	MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NVr2bJQzOjZyNUWzNFM>
ROSA KIT WT	M1jZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXm1MVUxODBibl2=	NHLCNmk1QCCq	NVHjfHFWTE2VTx?=	NFSxeFdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MXGyOlA2PTNyMx?=
ROSA KIT D816V	NIPKU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX:5UVI2PS13MECwJI5O	MWK0PEBp	M4PKdmROW09?	Mk\2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NHL4dlEzPjB3NUOwNy=>
HMC-1.1	MWrBdI9xfG:\|aYOgRZN{[Xl?	NXq0VXhUOjByLUWwNFAhdk1?	MUC0PEBp	MXPEUXNQ	NYrzW4dMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MVuyOlA2PTNyMx?=
HMC-1.2	MWLBdI9xfG:\|aYOgRZN{[Xl?	NGTF[3IzODBvNUCwNEBvVQ>?	NULi[pRqPDhiaB?=	M4POS2ROW09?	NHfTeYRqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NH;N[o4zPjB3NUOwNy=>
ROSA KIT WT	NEmyRXlCeG:ydH;zbZMhSXO\|YYm=	NF35SnkzODBvNUCwNEBvVQ>?	MUO0PEBp	M4jufmROW09?	MmjQbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MViyOlA2PTNyMx?=
ROSA KIT D816V	MYDBdI9xfG:\|aYOgRZN{[Xl?	M{fEWlIxOC13MECwJI5O	MYS0PEBp	NIXvVFdFVVOR	MVTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M2\xR\|I3ODV3M{Cz
494H	MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWW3NkBp	NHS1R\|FFVVOR	M4TuUWlEPTB;MD6xNlLDuTBwMEC0JO69VQ>?	MWiyOVk1PDV4Nh?=
493H	M{fKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXu3NkBp	M1TEVWROW09?	MWjJR\|UxRTBwMES3xtExNjByOTFOwG0>	MYGyOVk1PDV4Nh?=
716H	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{\OdVczKGh?	M{HSSmROW09?	NViyWVhmUUN3ME2wMlIyOsLzMD6wN\|Qh\|ryP	MlTmNlU6PDR3Nk[=
148I	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnXqO\|IhcA>?	NWroV45ITE2VTx?=	NIfOV\|dKSzVyPUCuNlg1yrFyLkCzOUDPxE1?	MkTuNlU6PDR3Nk[=
98Sc	M3XtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF7PTHE4OiCq	NEHiXFhFVVOR	NF7yOZdKSzVyPUCuNVE2yrFyLkCwOEDPxE1?	MYGyOVk1PDV4Nh?=
89R	MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV63NkBp	NHLKRVZFVVOR	NV3qfGpPUUN3ME2wMlEzPsLzMD6wNFMh\|ryP	MnfINlU6PDR3Nk[=
494L	MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{PE[lczKGh?	NWTpUZZ[TE2VTx?=	MoDhTWM2OD1yLkOxO:KyOC5yMUKg{txO	M4ewbFI2QTR2NU[2
493L	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHO5fGo4OiCq	M3XOZmROW09?	MWnJR\|UxRTBwMEWwxtExNjBzMTFOwG0>	NV6z[Zl4OjV7NES1OlY>
148L	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MW[3NkBp	M1TPbWROW09?	M1r3cWlEPTB;MD6xOFbDuTBwMEG3JO69VQ>?	M3P3Z\|I2QTR2NU[2
98L	NFTVPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVG3NkBp	MkXDSG1UVw>?	Mnr4TWM2OD1yLkOwPeKyOC5yMkmg{txO	NY[xWmdxOjV7NES1OlY>
OS17	M3HnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmDWO\|IhcA>?	MYnEUXNQ	MljiTWM2OD1yLkC3PeKyOC5yMEOg{txO	NV7H[JNZOjV7NES1OlY>
OS9	M4D3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4iyT\|czKGh?	Mni2SG1UVw>?	MXfJR\|UxRTBwNEC2xtExNjB{ODFOwG0>	M4TVXVI2QTR2NU[2
MG63	NVXVT4ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mm[5O\|IhcA>?	M3m4[WROW09?	MmPxTWM2OD1yLkGxOOKyOC5yMkWg{txO	MV:yOVk1PDV4Nh?=
SAOS2	M3K5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYLPNot{PzJiaB?=	MV7EUXNQ	NIfBTo9KSzVyPUCuNlE4yrFyLkCwN{DPxE1?	NUjQNZl{OjV7NES1OlY>
U2OS	NYi5O2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MU[3NkBp	NWTKUo9pTE2VTx?=	M1yyb2lEPTB;MD6xPVjDuTBwMEC4JO69VQ>?	M1fycFI2QTR2NU[2
SJSA-1	M2ftNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1vhbVczKGh?	M13ue2ROW09?	M3fFWGlEPTB;MD6xNFDDuTBwMEGwJO69VQ>?	MoqyNlU6PDR3Nk[=
494H	MXnBdI9xfG:\|aYOgRZN{[Xl?	MUewMlI2NzBwNT:xMlAh\|ryP	M{X3TlI1KGh?	MYjEUXNQ	MYXpcoNz\WG\|ZYOgcIV3\Wy\|IH;mJINt\WG4ZXSgZ4F{eGG\|ZT2zxsA>	MViyOVk1PDV4Nh?=
148I	MojZRZBweHSxc3nzJGF{e2G7	MoLvNE4zPS9yLkWvNU4xKM7:TR?=	NFPrVmMzPCCq	NEPOd2lFVVOR	M2XHTYlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>?	NIDjSGUzPTl2NEW2Oi=>
OS17	NV[xfIVCSXCxcITvd4l{KEG\|c3H5	NXfqWol6OC5{NT:wMlUwOS5yIN88US=>	NF2zUmgzPCCq	M1voTWROW09?	MYfpcoNz\WG\|ZYOgcIV3\Wy\|IH;mJINt\WG4ZXSgZ4F{eGG\|ZT2zxsA>	MmT5NlU6PDR3Nk[=
494H	NEP4[4tCeG:ydH;zbZMhSXO\|YYm=	Mlu3NgKBkc7:TR?=	NHrV[201QCCq	M2XrV2ROW09?	MmPsbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5	NGLic3YzPTl2NEW2Oi=>
148I	M1vJSGFxd3C2b4Ppd{BCe3OjeR?=	NXfZfmJkOeLCid88US=>	M4f1dVQ5KGh?	MY\EUXNQ	MnK4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5	MnjONlU6PDR3Nk[=
OS17	NHnYTWZCeG:ydH;zbZMhSXO\|YYm=	MYmx5qCK\|ryP	MnXSOFghcA>?	MY\EUXNQ	MXzpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm=	NIDlb20zPTl2NEW2Oi=>
MOLM13	M4TNcmFxd3C2b4Ppd{BCe3OjeR?=	MofLNlUxKG6P	MVu0PEBp	M3HhRWROW09?	MYHpcoR2[2W\|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ?	MYqyOVA2Ozh{NR?=
MV4-11	NV;RfG9{SXCxcITvd4l{KEG\|c3H5	NETr[FQzPTBibl2=	M4myclQ5KGh?	MVnEUXNQ	MV;pcoR2[2W\|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ?	NULaTHRtOjVyNUO4NlU>
MOLM13	MVzGeY5kfGmxbjDBd5NigQ>?	MnrhNlUxKG6P	NXvqbppiOjRiaB?=	NX;ReIgxTE2VTx?=	Mlnz[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS	NH\rfXYzPTB3M{iyOS=>
MV4-11	M1rP[GZ2dmO2aX;uJGF{e2G7	NVnnSlE2OjVyIH7N	M13t[VI1KGh?	MWLEUXNQ	MVLlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB?	M2q1bFI2ODV\|OEK1
MOLM13	M4[zc2Fxd3C2b4Ppd{BCe3OjeR?=	MWSyOVAhdk1?	NU\MNYN[PDhiaB?=	MmnBSG1UVw>?	NHTXTZBqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m\|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk	MonTNlUxPTN6MkW=
MV4-11	MkDiRZBweHSxc3nzJGF{e2G7	Mn\mNlUxKG6P	M4LxOFQ5KGh?	NEns[3dFVVOR	MYPpcoR2[2W\|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheG:wYYTpcolj	NWi4UWxxOjVyNUO4NlU>
Hela	MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NITteG4xNTVyMDDuUS=>	NWPLSWVXPzJiaB?=	NWrCWmQyTE2VTx?=	NFe2flVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXTmb2IyOjVyMEmyPVU>
HBL-1	MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NEDMPWIxNTVyMDDuUS=>	NWraN3R2PzJiaB?=	MXrEUXNQ	MXTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MnzzNlUxODl{OUW=
HLY-1	M4\QR2NmdGxiVnnhZoltcXS7IFHzd4F6	MYOwMVUxOCCwTR?=	Ml;nO\|IhcA>?	NXmwfpV5TE2VTx?=	NF7P[Hdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M3;od\|I2ODB7Mkm1
OCI-Ly3	NXf0RoIxS2WubDDWbYFjcWyrdImgRZN{[Xl?	MmXwNE02ODBibl2=	MkH6O\|IhcA>?	M4DRfmROW09?	MWfk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NWjOUHFpOjVyMEmyPVU>
OCI-Ly10	M1PT[2NmdGxiVnnhZoltcXS7IFHzd4F6	Mk\PNE02ODBibl2=	MYm3NkBp	NGOydnhFVVOR	NFK5T5Jl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M4GydVI2ODB7Mkm1
SU-DHL-4	MkfPR4VtdCCYaXHibYxqfHliQYPzZZk>	NEnpSW4xNTVyMDDuUS=>	M1T6flczKGh?	NU\SSXhTTE2VTx?=	MoDF[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	Mo\XNlUxODl{OUW=
SU-DHL-5	M2jVPWNmdGxiVnnhZoltcXS7IFHzd4F6	MYKwMVUxOCCwTR?=	NIX0OIE4OiCq	NF6yfpdFVVOR	NGnIOHhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MVGyOVAxQTJ7NR?=
SU-DHL-6	M2m5OGNmdGxiVnnhZoltcXS7IFHzd4F6	MmHHNE02ODBibl2=	M4XRblczKGh?	NILIOnZFVVOR	NX3USWFw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NW\6W4tyOjVyMEmyPVU>
SU-DHL-10	NWraV5JTS2WubDDWbYFjcWyrdImgRZN{[Xl?	Ml\uNE02ODBibl2=	MlXCO\|IhcA>?	MYDEUXNQ	M33QcYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3PQeVI2ODB7Mkm1
RC-K8	MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmrTNE02ODBibl2=	MmSxO\|IhcA>?	NEnmbFdFVVOR	NUntR\|M3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1;acFI2ODB7Mkm1
OCI-Ly8	NH[3XGtE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NF7aUJYxNTVyMDDuUS=>	M33rblczKGh?	NFrQS29FVVOR	Mn7y[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M2XMUVI2ODB7Mkm1
OCL-Ly18	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mlv0NE02ODBibl2=	NXTHU4wzPzJiaB?=	MVrEUXNQ	M1roPIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MWCyOVAxQTJ7NR?=
OCI-Ly3	MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrxVHhROTd{L{K1NE82ODBibl2=	M1K2SFIwPyCm	MmnNSG1UVw>?	MkLlbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW\|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?=	M1fpdVI2ODB7Mkm1
OCI-Ly8	NUT4N3dRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlKxNVczNzJ3MD:1NFAhdk1?	M3Pq[FIwPyCm	NUL6dpRVTE2VTx?=	MUfpcoR2[2W\|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi	MYSyOVAxQTJ7NR?=
SU-DHL-4	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHz1RWwyPzJxMkWwM\|UxOCCwTR?=	MXqyM\|ch\A>?	M1nlN2ROW09?	NEf1PXdqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg	MV:yOVAxQTJ7NR?=
SU-DHL-10	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1izR\|E4Oi9{NUCvOVAxKG6P	MWGyM\|ch\A>?	MnLqSG1UVw>?	NHvkW\|BqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg	NWDVclJ2OjVyMEmyPVU>
OCI-Ly3	M{LVSGFxd3C2b4Ppd{BCe3OjeR?=	MYWxO\|IwOjVyIH7N	MnK3O4Q>	MYnEUXNQ	MnnObY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC\|aXfubYZq[2GwdHz5	MWOyOVAxQTJ7NR?=
OCI-Ly8	M4\OOWFxd3C2b4Ppd{BCe3OjeR?=	NUDmO3ZGOTd{L{K1NEBvVQ>?	NFnrfWg4\A>?	NWq0UVh1TE2VTx?=	MXzpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zM\|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm=	NV;5WZlLOjVyMEmyPVU>
SU-DHL-4	NWqwVYZwSXCxcITvd4l{KEG\|c3H5	NYHhfHMyOTd{L{K1NEBvVQ>?	MkPjO4Q>	MoDFSG1UVw>?	M4HHVIlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=>	M3mzVVI2ODB7Mkm1
SU-DHL-10	MXHBdI9xfG:\|aYOgRZN{[Xl?	MYKxO\|IwOjVyIH7N	NHnQTGg4\A>?	MU\EUXNQ	NYW3[JpOcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6	M3zSU\|I2ODB7Mkm1

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; PubMed: 26119999 Chem Biol The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. c-Myc; PubMed: 23792448 Oncogene PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. p27; PubMed: 23792448 Oncogene Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.	26119999 23792448
Growth inhibition assay	Cell viability; PubMed: 23792448 Oncogene PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control.	23792448
Immunofluorescence	GM130; PubMed: 29074567 Mol Biol Cell Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. MHC / EdU; PubMed: 28733670 Sci Rep C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.	29074567 28733670

In vivo

(+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. ^[1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. ^[2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. ^[3]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: MC 11060 cells
Concentrations: ~500 nM
Incubation Time: 48 hours
Method:
Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: Mice bearing NMC 797 xenografts
Formulation: 5% DMSO in 5% dextrose
Dosages: 50 mg/kg
Administration: intraperitoneal injection
(Only for Reference)

References

[4] Li Z, et al. Nucleic Acids Res, 2013, 41(1), 277-287.

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (199.12 mM)
	Ethanol	91 mg/mL (199.12 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download (+)-JQ1 SDF

Molecular Weight	456.99
Formula	C₂₃H₂₅ClN₄O₂S
CAS No.	1268524-70-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CC1=C(C)C2=C(S1)[N]3C(=NN=C3C(CC(=O)OC(C)(C)C)N=C2C4=CC=C(Cl)C=C4)C

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can I reconstitute the compound for in vivo injection?
Answer:
JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Pan BET Inhibitor

Bromosporine : Pan-BET inhibitor, BRD2, IC50=0.41 μM; BRD4, IC50=0.29 μM; BRD9, IC50=0.122 μM; CECR2, IC50=0.017 μM.
BET Inhibitor in Clinical Trial

RVX-208 ^New : Phase II for Dyslipidemia.
Newest BET Inhibitor

I-BET-762 : Inhibitor for BET proteins with IC50 of ~35 nM, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.
Classic BET Inhibitor

I-BET151 (GSK1210151A) : Novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

(+)-JQ1